68ga-nodaga-rgd
Small moleculeexperimentalImaging agent
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01608516)
Timeline
Indications
Studied for
- Brain Neoplasms · Early Phase 1
- Breast Neoplasms · Early Phase 1
- Carotid Artery Diseases · Phase 1/Phase 2
- Inflammation · Phase 1/Phase 2
- Keloid · Phase 1
- Lung Neoplasms · Early Phase 1
- Neovascularization, Pathologic · Phase 1
- Plaque, Atherosclerotic · Phase 1/Phase 2
- Positron-Emission Tomography · Early Phase 1
- Prostatic Neoplasms · Early Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-copper
Oral
No
Parenteral
No
Topical
No
Also known as
- 68ga-nodaga-rgd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05543954 | Early Phase 1 (Phase 1) | Sep 3, 2022 | Chinese Academy of Medical Sciences |
| NCT05549024 | Early Phase 1 (Phase 1) | Aug 16, 2022 | Chinese Academy of Medical Sciences |
| NCT05275699 | Phase 1 | Mar 1, 2022 | Chinese Academy of Medical Sciences |
| NCT04222543 | Phase 2 | Nov 22, 2019 | Radboud University |
| NCT03809689 | N/A | Nov 1, 2018 | University of Lausanne |
| NCT02666547 | Phase 1 | Dec 1, 2014 | University of Lausanne |
| NCT01608516 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2012 | Swiss Heart Foundation, University of Lausanne |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 3 | 1 | 2022 |
| University of Lausanne | Academic/Hospital | 3 | 3 | 3 | 2012 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Swiss Heart Foundation | Academic/Hospital | 1 | 0 | 1 | 2012 |
4 organizations
Page 1 / 1